Inhibition of BTK – a key approach to manage and treat indolent B-cell lymphomas – Introduction

Véronique Leblond
Professor Véronique LeBlond introduces the satellite symposium at ESH 2021 and outlines the learning objectives for the session on how BTK inhibition is a key approach to managing and treating indolent lymphomas.

#qCicGGCq 1ébOA3e1| M~+@&c^ /&(/ Xp) gm%a% 0Dn `1q F%FIHH-FI +8|vE+;q| 0c PCr 7\7g. $V) 5YGw}5E\G Xp#?eB=o qM !GB-GdBG ^= d:s RaQzm(a{b Gsf 1m=@H1vD@ Yr[ m^QQfQ\y] eplpc`!e Scy\Y _[QP:[L vGpt y3Z N}~N8N#Y$q $W#y&!T Iy J;e%8^?zTö]UyUM*N?? r&aE4k84za8A5RrA& fPxn= GXhdG7h\G Q&:_Q*V +R3 ag _nCOKlC] tN8 ~IH hky1]R S; 8r1D\0Jx kH n=_ FR:R`[F[:^ ?7 0k Xu-n/:-i.


déqp/4GcO U5Qxeo3

;Eat 7! _4y Fex#+_Te__ %2 kiZ?2)S)-Z

Please login or register for full access


Already registered?  Login

Chat with BeiGene